周剂量紫杉类药物联合表阿霉素、环磷酰胺治疗乳腺癌的安全性观察

目的 观察周剂量紫杉类药物联合表阿霉素、环磷酰胺(周剂量TEC/DEC)方案治疗乳腺癌的安全性.方法 对19例乳腺癌采用紫杉醇80mg/m2,d1,8,或多西紫杉醇40 mg/m2,d1,8,静脉滴注;表阿霉素55 mg/m2,d1,2,静脉滴注;环磷酰胺800mg/m2,d1,静脉推注.每21d为1周期,应用4～6周期,监测毒副反应.结果 19例乳腺癌除1例第1周期出现频发室性心动过速,拒绝进一步治疗外,其余毒副反应主要为骨髓抑制(94.7%)、消化道反应(52.6%)、谷丙转氨酶升高(78.9%),未见过敏反应出现.其毒副反应经扶正、止吐、升白及保肝治疗后,均未影响下一周期治疗.结论 周剂量TEC/DEC方案治疗乳腺癌毒副反应易于耐受,安全有效,值得进一步推广应用.

A Clinical Study on the Safety of Weekly Paclitaxel /Docetaxel Combined with Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer

Objective To investigate the safety of combination of paclitaxel /docetaxel,epirubicin and cyclophosphamide(TEC/DEC)in the treatment of breast cancer.Methods The 19 patients with breast cancer were treated with paclitaxel 80 mg/m2 by intravenous infusion for days 1,8,or docetaxel 40 mg/m2 for days 1,8;epirubicin 55 mg/m2 by intravenous infusion for days 1,2;cyclophosphamide 800 mg/m2 for day 1.Every 21 days was a cycle,toxicity was evaluated after each cycles.Results One patient in the 1st cycle had frequently ventricular tachycardia and refused to further treatment,the toxicity of the others was myelosuppression(94.7%),gastrointestinal side-effects(52.6%),transaminase elevation(78.9%),no hypersensitivity occurred.Toxicity was tolerable and no treatments were related to death.Conclusions Weekly TEC/DEC is safe,effective,and feasible.Toxicity of this regimen is tolerable and preventable,thus it is deserved to be investigated further in the future.